Zoetis Business Summary

Zoetis Inc. (ZTS) is the global leader in the animal health industry, generating revenue through the discovery, development, and commercialization of a diverse portfolio of medicines, vaccines, diagnostics, and precision technologies for both companion animals and livestock. The company’s operations are divided into two primary geographic segments—the United States and International—which are further categorized by species. As of early 2026, the Companion Animal segment (dogs, cats, and horses) contributes approximately 65% of total revenue, driven by blockbuster franchises in parasiticides, dermatology, and pain management, while the Livestock segment (cattle, swine, poultry, and fish) accounts for the remaining 35%. Zoetis maintains a dominant market position with an estimated 20% global market share, consistently outperforming the industry average. Its primary direct competitors include Merck Animal Health, Elanco Animal Health, Boehringer Ingelheim, and IDEXX Laboratories, against whom Zoetis differentiates itself through its extensive direct-to-veterinarian sales force and a robust R&D pipeline focused on monoclonal antibodies and digital health solutions. Originally established as a spin-off of Pfizer’s animal health unit in 2012, Zoetis is currently led by Chief Executive Officer Kristin Peck, who has served in the role since 2020 and previously held senior leadership positions at Pfizer. The executive team includes Wetteny Joseph as Chief Financial Officer and Dr. Kevin Esch, who was appointed Executive Vice President and President of Research and Development effective January 1, 2026, bringing over a decade of veterinary and pharmaceutical expertise to the company’s scientific strategy. The Board of Directors features notable industry veterans such as Frank D’Amelio, the former CFO of Pfizer, and Stephanie Tilenius, a prominent technology executive. The company maintains high institutional backing, with major shareholders including Vanguard and BlackRock, reflecting its status as a core holding in the healthcare and veterinary sectors.